AEZS Aeterna Zentaris Inc.

-0.06  -1%
Previous Close 4.31
Open 4.34
Price To Book 37.3
Market Cap 68893635
Shares 16,210,267
Volume 139,195
Short Ratio
Av. Daily Volume 274,393

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3 trial did not meet primary endpoint - May 1, 2017.
Endometrial cancer

Latest News

  1. Aeterna Zentaris: 4Q Earnings Snapshot
  2. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results
  3. Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019
  4. Aeterna Zentaris (AEZS) Moves to Buy: Rationale Behind the Upgrade
  5. The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie
  6. Aeterna Zentaris Announces Strategic Review and Engagement of Financial Advisor
  7. What's in the Cards for Aeterna (AEZS) This Earnings Season?
  8. The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
  9. 4 Drug Stocks to Buy Despite Price Hearing Woes
  10. The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
  11. 5 Tiny Biotech Stocks With Superb Growth Potential
  12. Is AEterna Zentaris (AEZS) Outperforming Other Medical Stocks This Year?
  13. Implied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options
  14. Aeterna Zentaris Receives European Marketing Clearance for Macimorelin
  15. Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan
  16. Aeterna Zentaris (AEZS) Stock Moves -1.16%: What You Should Know
  17. Aeterna Zentaris Settles Dispute with David Dodd and Philip Theodore
  18. Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
  19. Aeterna Zentaris (AEZS) Gains As Market Dips: What You Should Know